XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Convertible Loan Notes (Additional Information) (Details)
£ / shares in Units, £ in Millions
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Feb. 10, 2023
USD ($)
shares
Feb. 10, 2020
GBP (£)
£ / shares
shares
May 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Sep. 30, 2023
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2023
£ / shares
Dec. 31, 2020
£ / shares
Feb. 10, 2020
USD ($)
shares
Ordinary Shares | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Exercise Price of Warrants Issued | £ / shares   £ 0.265                      
Novartis Loan Note [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Interest Rate   6.00%                     6.00%
Carrying Value of Debt Instrument       $ 4,900,000     $ 4,900,000     $ 4,400,000      
Fair value of convertible debt       $ 3,300,000     $ 3,300,000     $ 3,100,000      
Debt Instrument, Effective Interest Rate       27.80%   27.80% 27.80% 27.80%          
Novartis Loan Note [Member] | After Amendments [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Effective Interest Rate           37.40%   37.40%          
Novartis Loan Note [Member] | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Amount of Convertible Note   £ 3.8                     $ 5,200,000
Conversion Price Per Share | £ / shares   £ 0.265                      
Debt Instrument, Maturity Date   Feb. 10, 2023                      
Warrants Convertible in Equity | shares   1,449,614                     1,449,614
Debt Instrument, Extended Maturity Date Feb. 10, 2025                        
Debt Instrument, Amended Interest Rate 9.00%                        
Debt Instrument, Amended Accrued Interest $ 900,000                        
Novartis Loan Note [Member] | Ordinary Shares | Novartis Pharma [Member]                          
Debt Instrument [Line Items]                          
Warrants Convertible in Equity | shares 2,000,000                        
New Novartis Loan Note [Member]                          
Debt Instrument [Line Items]                          
Carrying Value of Debt Instrument $ 5,500,000                        
Debt Instrument, Consideration, Liability Recognised Two 3,400,000                        
Debt Instrument, Interest Paid in Cash 900,000                        
Relative Fair value of the Warrants and The Conversion Option 1,200,000                        
Gain (Loss) on Extinguishment of Debt $ 0                        
Debt, Interest Expense       $ 300,000   $ 200,000 $ 600,000 $ 500,000          
Convertible Debt Instrument [Member] | Private Placement Loan Notes [Member]                          
Debt Instrument [Line Items]                          
Debt Instrument, Interest Rate                       6.00%  
Debt Instrument, Maturity Date                 Jun. 03, 2023        
Debt Instrument, Extended Maturity Date     Aug. 03, 2023                    
Debt, Interest Expense           $ 700,000   $ 1,100,000          
Debt Instrument, Effective Interest Rate       27.10%     27.10%     25.10%      
Debt Instrument, Aggregate Principal Amount       $ 4,600,000     $ 4,600,000            
Issuance of Private Placement Loan Notes                 $ 70,000,000        
Changes in Carrying Value of Debt Instrument     $ 600,000                    
Payment of Debt Outstanding Amount                   $ 3,200,000      
Convertible Debt Instrument [Member] | Ordinary Shares | Private Placement Loan Notes [Member]                          
Debt Instrument [Line Items]                          
Conversion Price Per Share | £ / shares                       £ 0.174  
Debt Instrument,Conversion, Shares Issued | shares         9,645,200 17,774,895              
Share Issued, Price per Share | £ / shares                     £ 0.174